Your hub to the latest Knowledge in Nuclear Medicine/Molecular Imaging

Press releases

Hermes Medical Solutions receives EU MDR certificate and CE marking for its medical software applications

Hermes Medical Solutions (HMS), a global market leader in molecular imaging and dosimetry software, has received its EU Medical Device Regulation (MDR) certificate. All upcoming releases of our software applications for Nuclear Medicine, Molecular Imaging and dosimetry are compliant with the new European legislation for medical devices software. 

Hermes Medical Solutions releases a new version of the Hermia Multimodality Viewer software in North America

Hermes Medical Solutions (HMS), global market leader in molecular imaging and dosimetry software solutions, launches the latest version of its Hermia Multimodality Viewing Software, in Canada and in the USA. 

Hermes Medical Solutions is happy to announce its donation of molecular imaging/nuclear medicine software to Regis College.

“We see it as part of our mission as a leading provider of Molecular Imaging Software to provide the future generation of nuclear medicine professionals with the latest tools, especially as this area of medicine is evolving at a rapid pace and needs to attract specialized professionals,” said Tom Francke, CEO at Hermes Medical Solutions.

Scientific publications

Anatomically guided reconstruction improves lesion quantitation and detectability in bone SPECT/CT

Bone single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging suffers from poor spatial resolution, but the image quality can be improved during SPECT reconstruction by using anatomical information derived from CT imaging.

Comparison of reprojected bone SPECT/CT and planar bone scintigraphy for the detection of bone metastases in breast and prostate cancer.

The aim of this study was to compare reprojected bone SPECT/CT (RBS) against planar bone scintigraphy (BS) in the detection of bone metastases in breast and prostate cancer patients.

Total Tumor Volume on F18-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with Ac.225-PSMA-I&T

PSMA-based alpha therapy using 225Ac-PSMA-I&T provides treatment for metastatic castration-resistant prostate cancer (mCRPC), even after the failure of 177Lu-PSMA radioligand therapy (RLT). In clinical routine, the total tumor volume (TTV) on PSMA PET impacts therapy outcomes and plays an increasing role in mCRPC patients. Hence, we aimed to assess TTV and its changes during 225Ac-PSMA-I&T RLT.


Theranostics Brochure

Brochure dedicated to the advanced tools for Theranostics and Therapies within the Hermia software.

Hermia product overview

Product overview of Hermia, a state-of-the-art software suite that supports all clinical scenarios in NM/MI on all cameras.

Future Liver Remnant Function

Ensure the best outcome for your patients undergoing major liver resection

White papers

Hermia SPECT Reconstruction

The quality of SPECT imaging is reduced by photon attenuation, resolution loss due to collimator-detector blur, photon scatter, and noise. All these factors limit both the visual quality and quantitative power of SPECT images. Hermia SPECT Reconstruction provides methods to compensate for the effects of the aforementioned four factors by modelling them in iterative reconstruction.

Hermia Advanced Bone SPECT Reconstruction

Our easy-to-use software enables precise determination of reconstruction parameters, and we are proud to be able to offer two Bayesian reconstruction algorithms to optimise your bone SPECT/CT images: AMAP-Smooth and AMAP-RDP.